The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
March 27th 2024
Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
February 27th 2024
Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM
June 25th 2022Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).
Read More
Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma
June 19th 2022Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.
Read More
Vitamin D Provides Therapeutic Benefit Among Patients With MM, Review Says
June 15th 2022A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.
Read More
High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study
June 4th 2022As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
Read More
Low Socioeconomic Status May Account for Ethnic Survival Disparities in MM
June 3rd 2022The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.
Read More
Serum IgG Subclass May Be Indicator of Treatment Effect in Multiple Myeloma
May 18th 2022The researchers found that among subclasses, IgG1 expression was most prominent in samples from patients with multiple myeloma, and expression of IgG1 changed significantly before, throughout, and following treatment.
Read More
Repurposing a Drug Used for Alcohol Abuse May Overcome MM Treatment Resistance
May 15th 2022According to recent findings, metabolizing disulfiram into diethyldithiocarbamate-copper complex creates a proteasome inhibitor-like treatment that enables the efficient killing of treatment-resistant multiple myeloma (MM) cells.
Read More
PET/CT Can Assess Early Treatment Response in Newly Diagnosed MM
May 12th 2022Negative positron emission tomography/CT examinations 6 months after induction therapy in patients with newly diagnosed multiple myeloma (MM) is associated with prolonged time to next treatment and overall survival.
Read More
Levels of Certain Thyroid Hormone May Help With Risk Stratification in MM
May 4th 2022With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
Read More